Mayne Pharma Group Adds to the Dermatology Pipeline

  • Nov 19, 2019 AEDT
  • Team Kalkine

Mayne Pharma Group Limited (ASX: MYX) has secured licensed rights to a generic topical dermatology product from Encube Ethicals Pvt Ltd. Encube has an outstanding track record of innovative and generic topical drug development.

  • New product is complementary to the company’s existing portfolio of branded and generic dermatology products.
  • Applications for the product approval are filed with US Food and Drug Administration, which is expected in calendar year 2020.

By 12:58 PM AEST, MYX was trading at $0.56, down by 0.88% relative to the previous close.


All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK